FDA Clearance Tracker · P170011-S025
Impella RP System
Last checked: Nov 20, 2026Latest source record: Aug 4, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Aug 4, 2020
Approved
Time to decision
50 days
Received Jun 15, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170011-S025
- Device name
- Impella RP System
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Jun 15, 2020
- Decided
- Aug 4, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P170011
Device type
- Device class
- Class III
- Regulation
- 21 CFR 870.4360
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for a labeling change related to the Impella RP best practice selection algorithm.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.